Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation

Slides:

Advertisements

Similar presentations

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

Advertisements

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD by Ana C. Alho, Haesook T.

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults

Cord-Blood Hematopoietic Stem Cell Transplant Confers an Increased Risk for Human Herpesvirus-6-Associated Acute Limbic Encephalitis: A Cohort Analysis

Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults

Vaccination of Children following Allogeneic Stem Cell Transplantation

Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation Joseph H. Antin, Eva C. Guinan,

Biology of Blood and Marrow Transplantation

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years Areej El-Jawahri, Shuli Li, Joseph.

Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation

Bradley W. Blaser, Haesook T. Kim, Edwin P. Alyea, Vincent T

Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic.

Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury Corey Cutler, Haesook T. Kim, Shaké Ayanian, Gary Bradwin, Carolyn Revta,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Daniela Ion, Kristen Stevenson, Sook-Bin Woo, Vincent T

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner,

B Cells in Chronic Graft-versus-Host Disease

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation Albert C.

A Comparison of the Kinetics of Nucleated Cells and CD34+ Cells in Neonatal Peripheral Blood and Cord Blood Joong-Pyo Kim, Young-Ho Lee, Young-Ah Lee,

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Nienke M. G. Rorije, Margaret M. Shea, Gowri Satyanarayana, Sarah P

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H

Claudio G. Brunstein, Bruce R. Blazar, Jeffrey S

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases Elizabeth O. Stenger, Kuang-Yueh Chiang, Ann.

Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients Nicolas.

Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation Karen Ballen, Adam M. Mendizabal, Corey Cutler, Ioannis Politikos,

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute.

Sarah Nikiforow, Jerome Ritz

Reprint of: B Cells in Chronic Graft-versus-Host Disease

B Cells and Transplantation: An Educational Resource

Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome Haesook T. Kim, Philippe Armand,

Cellular Immune Reconstitution and Its Impact on Clinical Outcome in Children with β Thalassemia Major Undergoing a Matched Related Myeloablative Allogeneic.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease Caron A. Jacobson, Lixian Sun, Haesook.

An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J

Merve Postalcioglu, Haesook T. Kim, Faruk Obut, Benjamin C

Pauline Damien, David S. Allan

Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease by Jennifer S. Whangbo, Haesook.

What is quality in a transplant program?

The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Karim E. Abou-Nassar, Haesook.

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Recovery of Circulating T-Follicular Helper Cells after Hematopoietic Stem Cell Transplantation Edouard Forcade, MD, Steven Paula, Kristen Cowens, Marta.

Karen K. Ballen, Thomas R. Spitzer, Beow Y

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:

Varicella-Zoster Virus Disease Is More Frequent after Cord Blood Than after Bone Marrow Transplantation Kristel Vandenbosch, Philippe Ovetchkine, Martin.

John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, Julie Aldridge,

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human.

Sarah Nikiforow, Haesook T

A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation Mark H. Kirschbaum,

Mary Eapen Biology of Blood and Marrow Transplantation

Correlation of Infused CD3+CD8+ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation Filippo Milano, Shelly Heimfeld, Ted Gooley,

Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation Philippe Armand, Haesook T. Kim, Joanna Rhodes,

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation Lindsey E.

Presentation transcript:

Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation Caron A. Jacobson, Amin T. Turki, Sean M. McDonough, Kristen E. Stevenson, Haesook T. Kim, Grace Kao, Maria I. Herrera, Carol G. Reynolds, Edwin P. Alyea, Vincent T. Ho, John Koreth, Philippe Armand, Yi-Bin Chen, Karen Ballen, Robert J. Soiffer, Joseph H. Antin, Corey S. Cutler, Jerome Ritz Biology of Blood and Marrow Transplantation Volume 18, Issue 4, Pages 565-574 (April 2012) DOI: 10.1016/j.bbmt.2011.08.018 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Reconstitution of CD3, CD4, and CD8 T cells after stem cell transplantation. Median absolute CD3 (A), CD4 (B), and CD8 (C) T cells/μL at 1, 2, 3, 6, 9, 12, 18, and 24 months after DUCB (blue lines) and MUD (pink lines) transplantation. The sample sizes at each time point are 26 versus 81, 27 versus 88, 33 versus 77, 35 versus 65, 20 versus 54, 31 versus 52, 11 versus 34, and 14 versus 23, for DUCB and MUD cohorts, respectively. The range of absolute CD3, CD4, and CD8 T cell counts in our normal healthy control cohort is represented in gray. ∗Indicates differences that are statistically significant (P < .05). Biology of Blood and Marrow Transplantation 2012 18, 565-574DOI: (10.1016/j.bbmt.2011.08.018) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Reconstitution of CD19 and CD20 B cells after stem cell transplantation. Median absolute CD19 B cells/μL (A), and CD56CD16 NK cells/μL (B) at 1, 2, 3, 6, 9, 12, 18, and 24 months after DUCB (blue lines) and MUD (pink lines) transplantation. The sample sizes at each time point are 27 versus 80, 27 versus 88, 33 versus 77, 35 versus 64, 20 versus 54, 31 versus 53, 11 versus 34, and 14 versus 23, for DUCB and MUD cohorts, respectively. The range of absolute CD19 B cell and CD56CD16 NK cell counts in our normal healthy control cohort is represented in gray. ∗Indicates differences that are statistically significant (P < .05). Biology of Blood and Marrow Transplantation 2012 18, 565-574DOI: (10.1016/j.bbmt.2011.08.018) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Reconstitution of T cell subsets after stem cell transplantation. Median absolute CD4CD45RO− naive (A), CD4CD45RO+ memory (B), and CD4CD25 regulatory (C) T cells/μL, and CD3CD56 cells/μL (D) at 1, 2, 3, 6, 9, 12, 18, and 24 months after DUCB (blue lines) and MUD (pink lines) transplantation. The sample sizes at each time point are 21 versus 79, 20 versus 88, 22 versus 77, 24 versus 64, 3 versus 53, 17 versus 52, 3 versus 34, and 6 versus 23, for DUCB and MUD cohorts, respectively. The range of absolute naïve, memory, and regulatory T cells and CD3CD56 cells in our normal healthy control cohort is represented in gray. ∗Indicates differences that are statistically significant (P < .05). Biology of Blood and Marrow Transplantation 2012 18, 565-574DOI: (10.1016/j.bbmt.2011.08.018) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Reconstitution of myeloid and plasmacytoid dendritic cells after stem cell transplantation. Absolute and median absolute CD11c myeloid (A) and CD123 plasmacytoid (B) dendritic cells/μL at 6 and 12 months after DUCB (blue diamonds) and MUD (pink circles) transplantation. The sample sizes at each time point are 6 versus 31, and 9 versus 26 for DUCB and MUD cohorts, respectively. ∗Indicates differences that are statistically significant (P < .05). Biology of Blood and Marrow Transplantation 2012 18, 565-574DOI: (10.1016/j.bbmt.2011.08.018) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Immunoglobulin levels after stem cell transplantation. Median serum IgG levels in mg/dL at 1-month intervals after transplantation from 1 month to 1 year after DUCB (blue line) and MUD (pink line) transplantation. The sample sizes at each 1-month time point are 50 versus 113, 44 versus 106, 32 versus 87, 44 versus 61, 36 versus 75, 36 versus 60, 34 versus 55, 27 versus 56, 22 versus 53, 18 versus 52, 23 versus 53, and 14 versus 49 for DUCB and MUD cohorts, respectively. The range of normal IgG levels is represented in gray. Biology of Blood and Marrow Transplantation 2012 18, 565-574DOI: (10.1016/j.bbmt.2011.08.018) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 Levels of BAFF and BAFF/CD19 B cells after stem cell transplantation. Median levels of BAFF in ng/mL (A), and BAFF/CD19 B cells (B) at 1, 3, 6, and 12 months after DUCB (blue lines) and MUD (pink lines) transplantation. The sample sizes at each time point are 22 versus 77, 30 versus 71, 21 versus 59, and 25 versus 37 for DUCB and MUD cohorts, respectively. The range of normal BAFF and BAFF/CD19 B cell ratios are represented in gray [24]. ∗Indicates differences that are statistically significant (P < .05). Biology of Blood and Marrow Transplantation 2012 18, 565-574DOI: (10.1016/j.bbmt.2011.08.018) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions